We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: breast cancer
MedXY News
EnglishTag

breast cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis
Hematology-Oncologybreast cancerneoadjuvant chemotherapy

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis

By MedXY|Oct 18, 2025

This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.

Assessing the Nationwide Prevalence and Outcomes of Breast Cancer Patients Eligible for Adjuvant CDK4/6 Inhibitors
OB/GYN & Women's Healthbreast cancerCDK4/6 inhibitors

Assessing the Nationwide Prevalence and Outcomes of Breast Cancer Patients Eligible for Adjuvant CDK4/6 Inhibitors

By MedXY|Oct 18, 2025

This study offers insights into the prevalence, characteristics, and long-term survival of breast cancer patients eligible for adjuvant CDK4/6 inhibitors, highlighting real-world outcomes compared to clinical trial populations.

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data
newsbreast cancerprognostication

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

By MedXY|Oct 15, 2025

This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.

Quantifying Breast Cancer Risk: The Impact of Pathogenic Variants and Family History in US Women
newsbreast cancerfamily history

Quantifying Breast Cancer Risk: The Impact of Pathogenic Variants and Family History in US Women

By MedXY|Oct 10, 2025

This study evaluates cumulative breast cancer risks among US women based on pathogenic variant status and family history, revealing significant risk stratification that informs personalized screening and prevention.

Rising Incidence of Breast Cancer Among Young Women: Trends and Implications from 1990 to 2023
Oncologybreast cancerincidence trends

Rising Incidence of Breast Cancer Among Young Women: Trends and Implications from 1990 to 2023

By MedXY|Oct 9, 2025

Early-onset breast cancer incidence in France has steadily increased over the past three decades, mirroring trends in other Western countries. Shifts in hormonal and lifestyle factors may contribute, highlighting the need for adapted preven

Impact of Immediate Past Mammography Participation on Outcomes of Screen-Detected Breast Cancer
newsbreast cancerMammography Screening

Impact of Immediate Past Mammography Participation on Outcomes of Screen-Detected Breast Cancer

By MedXY|Oct 6, 2025

This cohort study reveals that women with screen-detected breast cancer who missed the immediate prior mammography screening have larger tumors, more advanced disease, and worse breast cancer-specific survival, suggesting delayed detection

Clinical Updatesbreast cancergut microbiota

Deciphering the Role of Intratumoral Microbiota in Breast Cancer: Pathogenesis to Precision Therapeutics

By MedXY|Sep 30, 2025

Intratumoral microbiota significantly influence breast cancer development, progression, and therapeutic response. Their diverse composition across subtypes presents diagnostic and prognostic opportunities. Emerging strategies target these m

Novel Heparanase Inhibitor LMW-DSS Shows Promise in Preventing Breast Cancer Metastasis by Targeting Migration and Angiogenesis
Clinical Updatesangiogenesisbreast cancer

Novel Heparanase Inhibitor LMW-DSS Shows Promise in Preventing Breast Cancer Metastasis by Targeting Migration and Angiogenesis

By MedXY|Sep 30, 2025

Low-molecular-weight dextran sulfate sodium (LMW-DSS), a new heparanase inhibitor, effectively prevents breast cancer metastasis in mice by inhibiting cancer cell migration and angiogenesis, offering a promising therapeutic approach with mi

Evolving Trends and Economic Implications of Breast Cancer Screening in Older US Women: Navigating Value and Cost
OB/GYN & Women's Healthbreast cancerCost-Effectiveness

Evolving Trends and Economic Implications of Breast Cancer Screening in Older US Women: Navigating Value and Cost

By MedXY|Oct 6, 2025

Breast cancer screening among older US women shows stable use but rising costs driven by low-value technologies; optimizing screening strategies could enhance value and reduce expenditure.

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?
Clinical UpdatesHormone Receptor-PositiveRibociclib

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

By MedXY|Oct 9, 2025

Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review
Clinical Updatesbreast cancercognitive decline

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

By MedXY|Oct 6, 2025

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone thera

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial
Cardiologybreast cancerCardiotoxicity

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

By MedXY|Oct 6, 2025

The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial st

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence
newsbreast cancerEverolimus

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

By MedXY|Oct 6, 2025

A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast

Understanding Breast Cancer Risk: Habits and Genetic Factors That Quietly Increase Danger
Family Medicine & Nutritionbreast cancerearly detection

Understanding Breast Cancer Risk: Habits and Genetic Factors That Quietly Increase Danger

By MedXY|Oct 4, 2025

Breast cancer is the most common cancer among women, with 90% of patients belonging to high-risk groups. This article explores five major risk factors, early detection strategies, and lifestyle changes crucial for prevention.

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis
OB/GYN & Women's Healthbreast cancerElinzanetant

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY|Oct 4, 2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies
newsbreast cancerclinical trial

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

By MedXY|Oct 4, 2025

A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especial

Extending Endocrine Treatment Duration for Early Breast Cancer
newsaromatase inhibitorsbreast cancer

Extending Endocrine Treatment Duration for Early Breast Cancer

By MedXY|Oct 4, 2025

This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.

Advancing Breast Cancer Detection: AI Identifies Missed Interval Cancers on Mammograms
AIartificial intelligencebreast cancer

Advancing Breast Cancer Detection: AI Identifies Missed Interval Cancers on Mammograms

By MedXY|Oct 3, 2025

A recent study shows that an AI system can detect interval breast cancers missed by radiologists on mammograms, potentially improving early diagnosis and screening outcomes in women with dense breasts.

Breast Nodules: How Close Are They to Breast Cancer?
newsbreast cancerbreast nodules

Breast Nodules: How Close Are They to Breast Cancer?

By MedXY|Oct 1, 2025

This article explores the relationship between breast nodules and breast cancer, addressing common concerns and offering actionable health insights.

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance
Clinical Updatesbreast cancerendocrine resistance

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance

By MedXY|Oct 1, 2025

Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profil

Prev
3 / 4
1234
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities